The extensive exploration of further covariates, such as diagnosis (myeloproliferative disorders vs. others), donor type (matched‐related or mismatched‐related vs. others), HLA matching (identical vs. others), stem cell source (bone marrow vs. others), or CD34+ stem cell dose (e.g., < 5 × 106 cells vs. others), among other variables (TableS2), revealed minimal impact of patient and transplantation characteristics on post‐HCT platelet counts, except for total protein. Here, CD34 is linked to myeloproliferative disorder.